- Home
- CRTO vs CNTA Comparison
CRTO vs CNTA Comparison
Compare CRTO & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRTO
- CNTA
- Stock Information
- Founded
- CRTO 2005
- CNTA 2020
- Country
- CRTO France
- CNTA United Kingdom
- Employees
- CRTO N/A
- CNTA N/A
- Industry
- CRTO Advertising
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- CRTO Consumer Discretionary
- CNTA Health Care
- Exchange
- CRTO Nasdaq
- CNTA Nasdaq
- Market Cap
- CRTO 2.1B
- CNTA 1.8B
- IPO Year
- CRTO 2013
- CNTA 2021
- Fundamental
- Price
- CRTO $28.46
- CNTA $12.30
- Analyst Decision
- CRTO Buy
- CNTA Strong Buy
- Analyst Count
- CRTO 11
- CNTA 10
- Target Price
- CRTO $44.70
- CNTA $26.11
- AVG Volume (30 Days)
- CRTO 452.8K
- CNTA 628.0K
- Earning Date
- CRTO 05-02-2025
- CNTA 05-20-2025
- Dividend Yield
- CRTO N/A
- CNTA N/A
- EPS Growth
- CRTO 107.32
- CNTA N/A
- EPS
- CRTO 2.44
- CNTA N/A
- Revenue
- CRTO $1,934,668,000.00
- CNTA N/A
- Revenue This Year
- CRTO N/A
- CNTA N/A
- Revenue Next Year
- CRTO $7.92
- CNTA N/A
- P/E Ratio
- CRTO $11.64
- CNTA N/A
- Revenue Growth
- CRTO N/A
- CNTA N/A
- 52 Week Low
- CRTO $26.67
- CNTA $7.75
- 52 Week High
- CRTO $49.93
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- CRTO 37.97
- CNTA 40.97
- Support Level
- CRTO $26.97
- CNTA $11.88
- Resistance Level
- CRTO $28.98
- CNTA $14.39
- Average True Range (ATR)
- CRTO 1.62
- CNTA 0.79
- MACD
- CRTO -0.30
- CNTA -0.00
- Stochastic Oscillator
- CRTO 21.23
- CNTA 18.68
About CRTO Criteo S.A.
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.